1. Volume 141, Issue 6, Pages 2047-2055 (December 2011)
Efficacy of the Protease Inhibitor BI , Polymerase Inhibitor BI , and Ribavirin in Patients With Chronic HCV Infection 
Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean–Pierre Zarski, Dominique Larrey, Beat Müllhaupt, Ed Gane, Marcus Schuchmann, Ansgar Lohse, Stanislas Pol, Jean–Pierre Bronowicki, Stuart Roberts, Keikawus Arasteh, Fabien Zoulim, Markus Heim, Jerry O. Stern, George Kukolj, Gerhard Nehmiz, Carla Haefner, Wulf Otto Boecher 
Gastroenterology 
Volume 141, Issue 6, Pages (December 2011)
DOI: /j.gastro
Copyright © 2011 AGA Institute Terms and Conditions

2. Figure 1
Trial schema. eRVR, extended rapid virologic response (HCV RNA level ≤25 IU/mL at week 4, and HCV RNA undetectable from weeks 5 to 18); QD, once daily; TID, 3 times daily.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2011 AGA Institute Terms and Conditions

3. Figure 2 Patient disposition.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2011 AGA Institute Terms and Conditions

4. Figure 3
Absolute HCV RNA level from baseline to day 29 for individual patients in (A) the BI mg dose group and (B) the BI mg dose group. *Patient with virologic breakthrough observed during treatment at day 22. **Patient with an increase in HCV RNA from nadir of 0.7 log10 IU/mL. LLOD, 17 IU/mL; LLOQ, 25 IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2011 AGA Institute Terms and Conditions